## **ORIGINAL RESEARCH**

# Splanchnic Nerve Modulation Effects on Surrogate Measures of Venous Capacitance

Veraprapas Kittipibul <sup>(i)</sup>, MD; Arun Ganesh, MD; Aubrie Coburn, MS; Brian J. Coyne <sup>(i)</sup>, MEd; James Matthew Gray <sup>(i)</sup>, MS; Jeroen Molinger <sup>(i)</sup>, MS; Neil Ray, MD; Mihai Podgoreanu <sup>(i)</sup>, MD; Sharon L. McCartney, MD; Negmeldeen Mamoun <sup>(i)</sup>, MD; Robert Curtis Fitzhugh, BS; Philipp Lurz <sup>(i)</sup>, MD, PhD; Cynthia L. Green <sup>(i)</sup>, PhD; Adrian F. Hernandez <sup>(i)</sup>, MD; Manesh R. Patel <sup>(i)</sup>, MD; Marat Fudim <sup>(i)</sup>, MD, MHS

**BACKGROUND:** Splanchnic nerve modulation (SNM) is an emerging procedure to reduce cardiac filling pressures in heart failure. Although the main contributor to reduction in cardiac preload is thought to be increased venous capacitance in the splanchnic circulation, supporting evidence is limited. We examined changes in venous capacitance surrogates pre- and post-SNM.

**METHODS AND RESULTS:** This is a prespecified analysis of a prospective, open-label, single-arm interventional study evaluating the effects of percutaneous SNM with ropivacaine in chronic heart failure with elevated filling pressures at rest and with exercise. Patients underwent cardiopulmonary exercise testing with invasive hemodynamic assessment pre- and post-SNM. Blood pressure changes with modified Valsalva maneuver and hemoconcentration, pre- and post-SNM were compared using a repeated measures model. Inferior vena cava diameter and collapsibility (>50% decrease in size with inspiration), and presence of bendopnea pre- and post-SNM were also compared. Fifteen patients undergoing SNM (age 58 years, 47% women, 93% with left ventricular ejection fraction  $\leq$ 35%) were included. After SNM, changes in systolic blood pressure during Valsalva (peak-to-trough) were greater (41 versus 48 mmHg, *P*=0.025). Exercise-induced hemoconcentration was unchanged (0.63 versus 0.43 g/dL, *P*=0.115). Inferior vena cava diameter was reduced (1.59 versus 1.30 cm, *P*=0.034) with higher collapsibility (33% versus 73%, *P*=0.014). Bendopnea was less (47% versus 13%, *P*=0.025).

**CONCLUSIONS:** SNM resulted in increased venous capacitance, associated decreased cardiac preload, and decreased bendopnea. Minimally invasive measures of venous capacitance could serve as markers of successful SNM. Long-term effects of SNM on venous capacitance warrant further investigation for heart failure management.

REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03453151.

Key Words: heart failure E splanchnic nerve modulation E sympathetic nervous system E venous capacitance

The venous system contains ≈70% of the total blood volume.<sup>1</sup> Its greater compliance compared with the arterial system allows the venous circulation to function as both a conduit and a reservoir for intravascular blood volume. Veins are heavily innervated by adrenergic receptors of the sympathetic autonomic nervous system,<sup>2,3</sup> which enables the venous system to respond promptly to stimuli through changes in vascular capacitance and intravascular fluid redistribution.<sup>4</sup> By doing

so, venous circulation plays an important role in controlling central intravascular volume and cardiac preload. The splanchnic venous compartment, which consists of veins of the abdominal visceral organs, differs from other venous vascular beds. They are more compliant and contain a much larger volume of blood in comparison to the organ volume (up to 30% of total blood volume).<sup>5–7</sup> This reservoir of venous blood is also referred to as unstressed blood volume. With sympathoadrenal

Correspondence to: Marat Fudim, MD, MHS, Duke Clinical Research Institute, 2301 Erwin Rd, Durham, NC 27715. Email: marat.fudim@duke.edu This manuscript was sent to Ferhaan Ahmad, MD, PhD, Senior Associate Editor, for review by expert referees, editorial decision, and final disposition. Supplemental Material is available at https://www.ahajournals.org/doi/suppl/10.1161/JAHA.122.028780 For Sources of Funding and Disclosures, see page 9.

<sup>© 2023</sup> The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

JAHA is available at: www.ahajournals.org/journal/jaha

## CLINICAL PERSPECTIVE

### What Is New?

- Splanchnic nerve modulation resulted in increased venous capacitance as demonstrated by changes in the proposed surrogates: peakto-trough blood pressure changes during the Valsalva maneuver, inferior vena cava diameter and its collapsibility, self-reported bendopnea, and changes in hemoglobin level (hemoconcentration) after exercise.
- We observed lack of strong correlation between changes in venous capacitance surrogates and filling pressures both pre- and postsplanchnic nerve modulation.

## What Are the Clinical Implications?

- The proposed venous capacitance surrogates may be used to identify potential candidates for splanchnic nerve modulation therapy and as markers of successful interventions targeting venous capacitance.
- Venous capacitance surrogates might be helpful in managing patients with heart failure, yet further investigation is warranted.

## Nonstandard Abbreviations and Acronyms

IVC	inferior vena cava				
PCWP	pulmonary capillary wedge pressure				
SBV	stressed blood volume				
SNM	splanchnic nerve modulation				

stimulation, up to 800mL of blood (unstressed blood volume) can mobilize from the splanchnic blood pool to the systemic circulation (ie, autotransfusion) within seconds, producing a rapid increase in cardiac preload.<sup>8</sup> This increase in venous return or stressed blood volume (SBV) generally will increase cardiac output. However, in patients with heart failure (HF), fluid redistribution from splanchnic circulation could worsen central vascular congestion and lead to HF decompensation.<sup>9,10</sup>

Sympathetic nervous system-mediated changes in splanchnic venous capacitance and resultant fluid redistribution has been recognized as a potential therapeutic target in HF. Venous capacitance is reduced in HF due to an increased sympathetic tone.<sup>11-14</sup> Greater splanchnic nerve modulation is an emerging concept in the management of HF. The safety and efficacy of temporary splanchnic nerve modulation (SNM) were investigated in 2 proof-of-concept studies in patients with decompensated HF (Splanchnic HF-1)<sup>15,16</sup> and chronic HF (Splanchnic HF-2).<sup>17</sup> Temporary SNM lowered resting filling pressures and improved cardiac output in patients hospitalized for acute decompensated HF. In ambulatory HF, SNM reduced filling pressure at rest and during peak exercise with associated improvement in cardiac output. The observed hemodynamic changes were associated with a decrease in estimated stressed blood volume and an increase in estimated unstressed blood volume.<sup>18</sup> The observed hemodynamic changes post-SNM are believed to be due to an increase in splanchnic venous capacitance, yet mechanistic evidence supporting this hypothesis is limited. We sought to investigate several noninvasive clinical surrogate measures of splanchnic venous capacitance at rest and with exercise, before and after SNM. The proposed surrogate metrics of (splanchnic) venous capacitance are as follows: blood pressure (BP) changes during Valsalva maneuver, changes in inferior vena cava (IVC) diameter, hemoconcentration during exercise, and self-reported bendopnea.

## **METHODS**

Because of the sensitive nature of the data collected for this study, requests to access the data set from qualified researchers trained in human subject confidentiality protocols may be sent to the corresponding author.

## **Study Design and Population**

This is a prespecified analysis of the Splanchnic HF-2 trial (ClinicalTrials.gov NCT03453151). Splanchnic HF-2 is a prospective, open-label, single-arm study evaluating the effects of SNM in ambulatory HF. Eligible patients were enrolled at Duke University Medical Center (Durham, NC) from May 2018 to June 2019. Inclusion criteria were patients with HF who had been on guideline-directed medical therapy with persistent New York Heart Association class II/III symptoms. Patients were also required to have a resting mean pulmonary capillary wedge pressure (PCWP) ≥15 mmHg or ≥25 mmHg at peak exercise. Patients with chronic kidney disease stage 5 and those with increased risk of bleeding (ie, known coagulopathies, and those on oral anticoagulants or oral antiplatelet agents other than aspirin) were excluded. Qualified patients underwent a fluoroscopic-guided percutaneous SNM at the T12/L1 level with ropivacaine. The procedure was performed bilaterally in the first 5 cases and unilaterally in the subsequent 10 cases due to symptomatic orthostatic hypotension with bilateral SNM. The expected duration of sympatholytic effects was up to 24 hours. Invasive hemodynamics were measured with patients in the supine position at rest and during exercise before and after SNM. Following resting hemodynamics, patients

underwent supine cycle ergometry testing at a fixed workload of 20 W during a warm-up phase until patients reached a steady state of expired VO<sub>2</sub> or up to 7 minutes. After reaching steady state, patients continued to exercise, with a stepwise increase in workload of 20 W every minute until exhaustion. Hemodynamic assessment during exercise was performed at 20 W and at peak exercise. Cardiac output was assessed using the direct Fick method. Patients repeated the exercise protocol after SNM (after a 30-minute wait period) with a recovery time of 1 to 1.5 hours between exercise studies (Figure S1). Hemodynamic tracings were reviewed in a blinded fashion. Full details on exercise protocol and hemodynamic testing can be found in the original publication.<sup>17</sup> The study protocols were approved by the Duke University institutional review board, and all patients provided written informed consent.

## Measurements of Venous Capacitance Surrogates

In addition to invasive hemodynamics, patients underwent modified Valsalva maneuver testing at rest before and after SNM.<sup>19</sup> Patients used a mouthpiece with an aperture at the tip of the tube to permit the escape of a small amount of air. As changes in hemodynamics during the Valsalva maneuver greatly depend on patient's effort, patients were trained to perform the modified Valsalva maneuver before the actual test at each time point. After 1 test run and being observed at baseline to ensure mean arterial BP fluctuations to be <5 mmHg, patients blew into the tube for 10 seconds, after which patients resumed normal breathing. Arterial BP changes were observed for the subsequent 30 seconds. Changes in arterial BP from peak (Phase I) to trough (early Phase II) were evaluated before and 1 hour after SNM while still in the catheterization laboratory.

IVC diameter was measured with ultrasound at baseline and after forceful inspiration. Changes in IVC diameters were subsequently assessed, and patients were considered to have IVC collapsibility if there was >50% decrease in IVC diameter with forceful inspiration. The IVC assessment (diameter and collapsibility) was repeated within 1 hour after SNM. Images were reviewed in a blinded fashion. To minimize the impact of prolonged fasting on IVC parameters, we calculated IVC diameter/right atrial pressure ratio, which implies IVC capacitance pre- and post-SNM.

To assess for bendopnea, patients were seated and instructed to bend forward at the waist as if tying their shoes for at least 30 seconds. Patients were considered to have bendopnea if they reported shortness of breath while bending forward and breathing. The presence of bendopnea was reassessed after SNM. Patients were allowed to hydrate and eat before the assessment of bendopnea after SNM. To assess for the degree of hemoconcentration following exercise, hemoglobin levels were measured at rest and during peak exercise to calculate changes in hemoglobin level. The measurements were reassessed after patients underwent SNM. Measurements occurred within 1.5 hours of each other.

### **Statistical Analysis**

Continuous variables are presented using the mean and SD or median and range, as appropriate, based on the underlying distribution. Statistical comparisons between individual time points pre- and post-SNM used the paired t test for continuous variables and the McNemar's test for categorical variables. BP (systolic, diastolic, and pulse pressure) with Valsalva maneuver before and after SNM were analyzed using a repeated measures model adjusted for fixed-effects including baseline BP, test (baseline, peak or trough), time (preor post-SNM), and all possible 2-way interactions with a random intercept and compound-symmetry variance structure. A similar model for hemoconcentration was also used. Model results are presented using the leastsquares (LS) mean estimate or difference with 95% Cl. Post-hoc analysis was conducted to assess the correlation between venous capacitance surrogates and changes in PCWP from resting to peak exercise pre- and post-SNM using linear regression with the coefficient of determination presented ( $R^2$ ). Statistical analyses were performed using SAS version 9.4 (SAS, Institute, Inc., Cary, NC). A P value <0.05 was considered statistically significant.

### RESULTS

### **Baseline Characteristics**

A total of 15 patients were included in this analysis. The average age was 58±13 years; 7 (47%) were women, and 9 (60%) had ischemic cardiomyopathy (Table 1). Fourteen (93%) patients had left ventricular ejection fraction ≤35%. Mean NT-proBNP (N-terminal pro natriuretic peptide) was 2172 pmoL/L (range, 112– 9319 pmoL/L). Baseline invasive hemodynamics (at rest, pre-SNM) were the following: right atrial pressure 13.8±4.0mmHg, mean pulmonary artery pressure 40.5±12.3mmHg, and PCWP 28.3±7.6mmHg (Table 2). Average exercise time was 4:48±1:36minutes pre-SNM and 5:03±1:31 minutes post-SNM. Cardiopulmonary exercise parameters pre- and post-SNM are shown in Table 2.

# Blood Pressure Changes During Valsalva Maneuver

The modified Valsalva maneuver was performed in 11 patients (Table 3). At rest, the mean heart rate was

#### Table 1. Baseline Characteristics

Characteristics	Values
Sex (female)	7 (47)
Age, mean±SD, y	58±13
BMI, mean (range), kg/m <sup>2</sup>	32 (22–56)
Ischemic cardiomyopathy	9 (60)
Comorbidities	
Hypertension	5 (33)
Diabetes	4 (27)
Atrial fibrillation	8 (53)
LVEF	
≤35%	14 (93)
>35%	1 (8)
Laboratory profiles	
Creatinine, mean (range), mg/dL	1.2 (0.7–1.9)
BUN, mean (range), mg/dL	32 (22–56)
NT-proBNP, mean (range), pmol/L	2172 (112–9319)
Guideline-directed medical therapy	
Beta-blockers	15 (100)
ACE-I/ARB	11 (73)
Mineralocorticoid receptor antagonists	10 (67)
Implantable cardioverter-defibrillator	15 (100)

ACE-I indicates angiotensin-converting enzyme inhibitors; ARB, angiotensin-receptor blockers; BMI, body mass index; BUN, blood urea nitrogen; LVEF, left ventricular ejection fraction; and NT-proBNP, N-terminal pro natriuretic peptide.

elevated after SNM (pre-SNM 75±17 bpm and post-SNM 79±17 bpm, P=0.042) but no significant changes in resting arterial BP were seen (pre-SNM systolic blood pressure [SBP] 132±17 mmHg and post-SNM SBP 128±16 mmHg, P=0.201). There was no difference in both SBP and diastolic blood pressure in Phase I. In the early Phase II, the SBP dropped to a lower value post-SNM (98±27 mmHg) as compared with pre-SNM (112±18mmHg, P=0.006). No difference between pre- and post-SNM diastolic blood pressure were seen in the early Phase II (68±18 mm Hg versus 62±16mmHg, P=0.057). Changes from peak to trough SBP during the Valsalva maneuver were greater post-SNM (48±17 mmHg) compared with pre-SNM (41±19mmHg, LS mean difference: 7.87 [95% Cl, 1.08–14.65], P=0.025) (Figure S2 and S3). There was no difference in changes from peak to trough diastolic blood pressure during the Valsalva maneuver post-SNM (27±16mmHg) compared with pre-SNM (28±22mmHg, LS-mean difference: -0.33 [95% CI -11.90, 11.24], P=0.95). Pulse pressure, defined as difference between SBP and diastolic blood pressure, was unchanged from peak to trough during the Valsalva maneuver post-SNM (19±21 mmHg) compared with pre-SNM (12±14 mmHg, LS mean difference: 6.54 [95% CI, -2.88, 15.96], P=0.162).

## Inferior Vena Cava Changes and Self-Reported Bendopnea

Ultrasound-measured IVC diameter at rest was smaller post-SNM (1.6 $\pm$ 0.6 versus 1.3 $\pm$ 0.6 cm, *P*=0.016). Incidence of IVC collapsibility was higher post-SNM (33% versus 73%, *P*=0.034). The IVC diameter/right atrial pressure ratio was higher post-SNM (0.12 $\pm$ 0.04 versus 0.17 $\pm$ 0.06. *P*=0.014). Self-reported bendopnea rate decreased from 47% to 13% post-SNM (*P*=0.025). No patient developed new bendopnea post-SNM.

### Hemoconcentration

There was no difference in hemoglobin level at rest pre-SNM (12.9 $\pm$ 1.5g/dL) compared with post-SNM (12.8 $\pm$ 1.4g/dL, *P*=0.250). Hemoglobin level was lower at peak exercise post-SNM (13.5 $\pm$ 1.7 versus 13.2 $\pm$ 1.6g/dL, *P*=0.007). Less hemoconcentration was found post-SNM compared with pre-SNM (0.6 $\pm$ 0.4 versus 0.4 $\pm$ 0.4g/dL, LS mean difference: -0.19 [95% CI, -0.42, 0.05], *P*=0.115), but the difference was not statistically significant (Figure S4).

### Intervention-Specific Outcomes

Of 15 patients, first 5 patients underwent bilateral SNM, and the subsequent 10 patients underwent unilateral SNM. Valsalva maneuver was performed in only 1 patient in bilateral SNM. Therefore, the interventionspecific analysis on BP changes during Valsalva maneuver was not performed. Baseline hemodynamics and changes in other venous capacitance surrogates were compared pre- and post-SNM according to their interventions (Table S1).

### Correlation Between Venous Capacitance Surrogates and Changes in Filling Pressures During Exercise

There was no correlation between changes in BP during Valsalva (from peak to trough) and changes in PCWP during exercise (from resting to peak exercise) both pre-SNM ( $R^2$ =0.23, P=0.139) and post-SNM  $(R^2=0.21, P=0.152)$  (Figure A and B). IVC diameter was correlated with changes in PCWP post-SNM  $(R^2=0.28, P=0.044)$ , but correlation pre-SNM  $(R^2=0.26, P=0.26)$ P=0.053) was not found to be significant (Figure C and D). IVC collapsibility was correlated with changes in PCWP post-SNM (R<sup>2</sup>=0.48, P=0.004) but not pre-SNM (R<sup>2</sup>=0.20, P=0.093). Self-reported bendopnea was not correlated with changes in PCWP both pre-SNM ( $R^2$ =0.06, P=0.379) and post-SNM ( $R^2$ =0.08, P=0.321). Hemoconcentration following exercise was not correlated with changes in PCWP both pre-SNM (R<sup>2</sup>=0.08, P=0.319) and post-SNM (R<sup>2</sup><0.01, P=0.994) (Figure E and F).

	Baseline			Peak exercise			
	Pre-SNM	Post-SNM	P value	Pre-SNM	Post-SNM	P value	
Hemodynamics							
MAP, mm Hg	96.7±13.7	86.9±17.0	0.011	106.6±24.3	94±22.8	0.002	
RAP, mmHg	13.8±4.0	8.4±4.1	<0.001	23.2±6.2	15.4±7.8	<0.001	
mPAP, mmHg	40.5±12.3	32.7±13.8	<0.001	54.1±14.4	45.8±17.7	<0.001	
PCWP, mmHg	28.3±7.6	20.3±9.5	<0.001	34.8±10.0 25.1±10.7		<0.001	
SVR, dynes/s per cm <sup>-5</sup>	1947±825	1523±602	<0.001	1189±631 895±312		0.108	
CI, L/min per m <sup>2</sup>	1.9±0.6	2.3±0.7	0.077	3.4±1.2	3.8±1.1	0.069	
CPET parameters							
Workload, W				33±24	50±30	0.019	
Exercise time, min				4:48±1:36	5:03±1:31	0.181	
Peak VO <sub>2</sub> , mL/kg per min				9.1±2.5	9.8±2.7	0.053	
VE/VCO <sub>2</sub> slope, %				37.1±7.6	35.1±6.0 0.067		
RER				1.14±0.13	1.08±0.11	0.081	

Table 2. Invasive Hemodynamics and Cardiopulmonary Exercise Functional Parameters

Data are presented as mean±SD. Cl indicates cardiac index; CPET, cardiopulmonary exercise testing; mPAP, mean pulmonary artery pressure; PCWP, pulmonary capillary wedge pressure; RAP, right atrial pressure; RER, respiratory exchange ratio; SNM, splanchnic nerve modulation; and SVR, systemic vascular resistance.

### DISCUSSION

In this study, we evaluated changes in surrogate measures of venous capacitance following SNM. The primary observations from this study are as follows: (1) SNM resulted in more pronounced changes in SBP from peak to trough during Valsalva maneuver (41 versus 48 mm Hg). (2) Ultrasound-measured IVC diameter was smaller post-SNM (1.6 versus 1.3 cm) with higher incidence of IVC collapsibility. (3) Self-reported bendopnea rate was lower post-SNM (47% versus 13%). (4) Hemoglobin level at peak exercise was lower post-SNM (13.5 versus 13.2 g/dL), but there was no difference in the degree of hemoconcentration after exercise (0.6 versus 0.4 g/dL).

Recent secondary analysis of SNM trials (Splanchnic HF-1 and Splanchnic HF-2) provides a mechanistic insight into physiological alteration following SNM in decompensated and ambulatory HF. SNM was shown to reduce estimated stressed blood volume up to 0.5 L, and the reduction in estimated stressed blood volume was maintained throughout exercise.<sup>18</sup> The feasibility of permanent surgical SNM in HF with preserved ejection fraction was also investigated (Surgical Resection of the Greater Splanchnic Nerve in Subjects Having Heart Failure With Preserved Ejection Fraction, ClinicalTrials. gov NCT0371554). Permanent SNM reduced filling pressure at rest and during exercise at 3 months, with associated improvement in functional status and quality of life. Decreased venous capacitance with a consequent increase in SBV has been proposed as 1 of the important mechanisms of cardiac filling pressure elevations leading to HF decompensation<sup>6,11</sup> and is believed to be the primary target of SNM in relieving congestion in the HF population. Our investigation demonstrating changes in extracardiac parameters as surrogates of splanchnic venous capacitance supports this hypothesis.

The Valsalva maneuver is a commonly used physiological tool to assess autonomic function but can also serve as a surrogate of central intravascular blood volume (or SBV), cardiac filling pressures, and venous capacitance.<sup>20-23</sup> During Phase I, intrathoracic pressure rises, which transmits to the periphery and consequently leads to increased arterial BP (ie, peak BP). As straining continues, venous return that serves as cardiac preload decreases and so does arterial BP. This corresponds to early Phase II, during which we observe lowest arterial BP (ie, trough BP). A drop in arterial BP (peak-trough) is inversely related to central blood volume, where BP changes are more pronounced in patients with low central blood volume. Notably, post-SNM, patients experienced a higher resting heart rate, lower SBP during early Phase II, and greater excursions in SBP from Phase I (peak) to early Phase II (trough) than pre-SNM. This indicates lower central intravascular volume, with subsequent baroreflex activation (higher heart rate) after SNM, and supports our hypothesis that SNM leads to redistribution of blood into the splanchnic vascular compartment. In other words, the reduction in sympathetic tone to the splanchnic vascular compartment decreases cardiac preload and allows for greater stress-(Valsalva) induced pressure swings. A similar observation was made after renal denervation, where the sole hemodynamic alteration postsympathetic denervation was

Table 3.	Changes in Surrogates	of Venous Capacitance
----------	-----------------------	-----------------------

	Pre-SNM	Post-SNM	LS-mean difference (95% CI)	P value			
BP changes during Valsalva maneuver							
At rest							
HR, bpm	75±17	79±17		0.042			
SBP, mmHg	132±17	128±16		0.201			
DBP, mm Hg	77±14	72±12		0.06			
PP, mmHg	56±14	53±12		0.487			
Phase I							
SBP, mmHg	153±23	145±20		0.079			
DBP, mm Hg	95±21	89±22		0.104			
PP, mmHg	56±15	58±15		0.441			
Phase II (early)			·				
SBP, mmHg	112±18	98±27		0.006			
DBP, mmHg	68±18	62±16		0.057			
PP, mmHg	44±9	39±15		0.179			
Changes from Phase I (peak) to early II (trough)	Changes from Phase I (peak) to early II (trough)						
SBP, mmHg	41±19	48±17	7.87 (1.08 to 14.65)	0.025*			
DBP, mmHg	28±22	27±16	-0.33 (-11.90 to 11.24)	0.953*			
PP, mmHg	12±14	19±21	6.54 (–2.88 to 15.96)	0.162*			
IVC changes							
IVC diameter (cm) at rest	1.6±0.6	1.3±0.6		0.034			
IVC collapsibility (decrease >50% with inspiration)	5 (33%)	11 (73%)		0.014			
IVC diameter/RAP at rest	0.12±0.04	0.17±0.06		0.007			
Self-reported bendopnea	7 (47%)	2 (13%)		0.025			
Hemoconcentration							
Hemoglobin at rest, g/dL	12.9±1.5	12.8±1.4		0.250			
Hemoglobin at peak exercise, g/dL	13.5±1.7	13.2±1.6		0.007			
Hemoglobin changes after exercise, g/dL	0.6±0.4	0.4±0.4	-0.19 (-0.42 to 0.05)	0.115*			

Data are presented as mean±SD. BP indicates blood pressure; bpm, beats per minute; DBP, diastolic blood pressure; HR, heart rate; IVC, inferior vena cava; LS-mean, least-squares mean; PP, pulse pressure; RAP, right atrial pressure; SBP, systolic blood pressure; and SNM, splanchnic nerve modulation. \*P values calculated from repeated measures models.

a change in vascular compliance as measured by the Valsalva maneuver and not office or ambulatory BP.<sup>24</sup>

IVC assessment with ultrasound is increasingly used to monitor volume status in the setting of shock or congestion.<sup>25</sup> IVC dimension, particularly IVC area, has been shown to correspond to changes in fluid status.<sup>26</sup> Degree of respirophasic changes in IVC size (ie, IVC collapsibility) has also been demonstrated to inversely correlate with central venous pressure, which is a surrogate for central intravascular volume.<sup>27</sup> We observed a smaller IVC diameter post-SNM. Additionally, incidence of IVC collapsibility, defined as >50% decrease in IVC diameter with forceful inspiration, was higher post-SNM. Both findings of IVC assessment support the effect of SNM in reducing central intravascular volume.

Bendopnea has been described as a sign of increased filling pressure in patients with advanced HF.<sup>28</sup> As patients lean forward, intraabdominal pressure increases and, as a consequence, fluid returns from intraabdominal (splanchnic) reservoir to the heart, which further increases cardiac filling pressure and precipitates symptoms in those whose filling pressure is already high. SNM increased splanchnic venous capacitance, and thus in theory blunted fluid shifts with forward bending, which explains the lower rate of bendopnea post-SNM observed in this study.

Physiologically, exercise results in hemoconcentration (increase in hemoglobin during exercise), which can be observed in both healthy subjects and patients with HF. It was demonstrated that the degree of hemoconcentration appeared to be less in patients with HF ( $1.1\pm0.5$  g/dL versus  $0.6\pm0.4$  g/dL).<sup>29</sup> Exerciseinduced hemoconcentration can be explained by 2 causes. First, with exercise, plasma volume shifts from the intravascular space (within blood vessel) to the extravascular compartment (interstitial space) as a result of exercise-induced BP elevation and end-organ



Figure. Correlation between venous capacitance surrogates and changes in filling pressures during exercise pre- and post-SNM.

Changes in blood pressure (peak-trough) during the Valsalva maneuver: **A**, Pre-SNM, **B**, Post-SNM. Inferior vena cava diameter: **C**, Pre-SNM, **D**, Post-SNM. Changes in hemoglobin level after exercise: **E**, Pre-SNM, **F**, Post-SNM. SNM indicates splanchnic nerve modulation.

perfusion.<sup>30</sup> Second, exercise activates the sympathetic nervous system, resulting in splanchnic vasoconstriction via the neuronal and hormonal pathway. The spleen is a highly blood-rich organ, storing red blood cells at a higher hemoconcentration than the remainder of the circulating blood.<sup>31</sup> Sympathetic

stimulation of the spleen leads to splenic vascular and capsular contraction and expulsion of highly concentrated blood (autotransfusion), which leads to systemic hemoconcentration.<sup>32</sup> Hypothetically, SNM, which decreases splanchnic sympathetic outflow, should result in a smaller increase in hemoglobin level during exercise and less hemoconcentration. In this study, we observed a lower hemoglobin level at peak exercise post-SNM. Although the degree of hemoconcentration was less post-SNM, statistical significance was not met. This finding was not entirely unforeseen because the SNM only attenuates the sympathetic stimulation component of exercise-induced hemoconcentration, and this perhaps suggests that changes in hemoglobin level during exercise might not be an ideal surrogate of venous capacitance.

Overall, our findings using various indirect measures indicate a decrease in splanchnic venous capacitance as a key physiological alteration following SNM. We did a post-hoc analysis to evaluate correlation between venous capacitance surrogates and changes in filling pressures during exercise. We did not expect to see a strong correlation between these variables as pressures do not always correlate with volumes or volume capacitances.<sup>33</sup> From our analyses, we only observed significant correlation between the IVC diameter and IVC collapsibility with pressures post-SNM. Whether SNM renders a stronger pressure-volume relationship is possible and needs to be further investigated.

We believe our study has important clinical implications. Because SNM selectively affects splanchnic vascular compliance (mostly venous system), we have validated a battery of minimally invasive surrogate measures pre- and post-SNM that would allow us to assess vascular compliance. These measures could be used as additional markers of successful SNM or other interventions targeting venous capacitance. Considering the minimal correlation between venous capacitance and cardiac filling pressures as demonstrated in our study, it is of great importance to determine the role of venous capacitance in place of or in addition to commonly used filling pressures in clinical practice. Interval monitoring of these minimally invasive surrogates rather than invasively derived cardiac filling pressures might also be helpful in determining mid- or long-term treatment response and help guide further intervention.

This study has several limitations. First, the study intervention was unblinded and subject to unmeasured bias. Despite our attempt to minimize the bias by using blinded review of hemodynamics, and ultrasound parameters, the end point of bendopnea was still susceptible to bias. Second, modified Valsalva maneuver was performed in 11 out of 15 patients. Although we did the modified Valsalva training on all patients before the actual test, the Valsalva pressures could still

vary and lead to difference in BP independent of the intervention. Additionally, we modified the study intervention from bilateral to unilateral SNM after the first 5 cases, which resulted in only 1 patient in the bilateral SNM group having performed the Valsalva maneuver. This limits our ability to compare effects of the Valsalva maneuver between intervention groups. Nevertheless, the intervention-specific analyses were derived from a much smaller sample size and subject to being underpowered. Third, the exercise protocol in this study is more strenuous than those for a general HF population, which might have led to shorter exercise time. Furthermore, the exercise was repeated on the same day post-SNM. Changes in parameters post-SNM suggestive of decreased central intravascular volume could have been partly due to prolonged fasting or unrecognized effects of exercise. To minimize the effect of fasting on the above, the measurements were repeated with a minimal delay in time following SNM, or as in the case of bendopnea, patients were allowed to hydrate/eat after the SNM in the recovery area, yet the reduction in bendopnea was nevertheless present. To further minimize this potential confounder, we used a repeated measures model that accounted for differences in baseline values when assessing changes during exercise. Fourth, the reported parameters were not direct measures of splanchnic venous capacitance, although physiologically correlated. They are inevitably affected by other factors such as changes in total body volume or body habitus/positions. Finally, besides the correlation between changes in venous capacitance surrogates and filling pressures, we were unable to assess the clinical significance of these observed changes due to the temporary nature of the intervention, which limits the assessment of mid- or long-term clinical end points.

## CONCLUSIONS

We highlight measures that could be used to test for acute or chronic changes in (splanchnic) venous capacitance and serve as (objective) surrogate metrics of technical/therapeutic success. The present study shows that SNM resulted in greater changes in peakto-trough BP during the Valsalva maneuver, smaller ultrasound-measured IVC diameter with higher incidence of collapsibility, and less bendopnea. These findings support that SNM led to increased venous capacitance with associated decrease in cardiac preload/SBV. Long-term effects of SNM on venous capacitance warrant further investigation for the management of HF.

### **ARTICLE INFORMATION**

Received November 7, 2022; accepted June 26, 2023.

#### Affiliations

Division of Cardiology, Department of Medicine, Duke University, Durham, NC (V.K., A.C., B.J.C., J.M.G., J.M., R.C.F., A.F.H., M.R.P., M.F.); Department of Anesthesiology, Duke University Medical Center, Durham, NC (A.G., N.R., M.P., S.L.M., N.M.); Heart Center Leipzig at University Leipzig, Leipzig, Germany (P.L.); Biostatistics and Bioinformatics, Duke University Medical Center, Durham, NC (C.L.G.); and (C.L.G., A.F.H., M.R.P., M.F.), Duke Clinical Research Institute, Durham, NC.

### Sources of Funding

This study was supported by Translating Duke Health Award.

#### Disclosures

Dr Fudim was supported by the National Heart, Lung, and Blood Institute (NHLBI) (K23HL151744), the American Heart Association (20IPA35310955), Mario Family Award, Duke Chair's Award, Translating Duke Health Award, Bayer, Bodyport, and BTG Specialty Pharmaceuticals. He receives consulting fees from Abbott, Audicor, AxonTherapies, Bodyguide, Bodyport, Boston Scientific, CVRx, Daxor, Edwards LifeSciences, Feldschuh Foundation, Fire1, Gradient, Intershunt, NXT Biomedical, Pharmacosmos, PreHealth, Shifamed, Splendo, Vironix, Viscardia, and Zoll. The remaining authors have no disclosures to report.

#### **Supplemental Material**

Data S1.

### REFERENCES

- Gelman S. Venous function and central venous pressure: a physiologic story. *Anesthesiology*. 2008;108:735–748. doi: 10.1097/ ALN.0b013e3181672607
- Birch DJ, Turmaine M, Boulos PB, Burnstock G. Sympathetic innervation of human mesenteric artery and vein. *J Vasc Res.* 2008;45:323– 332. doi: 10.1159/000119095
- Racchi H, Schliem AJ, Donoso MV, Rahmer A, Zúñiga A, Guzmán S, Rudolf K, Huidobro-Toro JP. Neuropeptide Y Y1 receptors are involved in the vasoconstriction caused by human sympathetic nerve stimulation. *Eur J Pharmacol.* 1997;329:79–83. doi: 10.1016/s0014-2999(97)00160-x
- Fudim M, Yalamuri S, Herbert JT, Liu PR, Patel MR, Sandler A. Raising the pressure: hemodynamic effects of splanchnic nerve stimulation. J Appl Physiol (1985). 2017;123:126–127. doi: 10.1152/japplphysiol.00069.2017
- Hainsworth R. The importance of vascular capacitance in cardiovascular control. *Physiology*. 1990;5:250–254. doi: 10.1152/ physiologyonline.1990.5.6.250
- Fudim M, Hernandez AF, Felker GM. Role of volume redistribution in the congestion of heart failure. J Am Heart Assoc. 2017;6:e006817. doi: 10.1161/JAHA.117.006817
- Greenway CV, Lister GE. Capacitance effects and blood reservoir function in the splanchnic vascular bed during non-hypotensive haemorrhage and blood volume expansion in anaesthetized cats. *J Physiol.* 1974;237:279–294. doi: 10.1113/jphysiol.1974.sp010482
- Gelman S, Mushlin PS. Catecholamine-induced changes in the splanchnic circulation affecting systemic hemodynamics. *Anesthesiology*. 2004;100:434–439. doi: 10.1097/00000542-200402000-00036
- Burkhoff D, Tyberg JV. Why does pulmonary venous pressure rise after onset of LV dysfunction: a theoretical analysis. *Am J Phys.* 1993;265:H1819–H1828. doi: 10.1152/ajpheart.1993.265.5.H1819
- Fudim M, Neuzil P, Malek F, Engelman ZJ, Reddy VY. Greater splanchnic nerve stimulation in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2021;77:1952–1953. doi: 10.1016/j.jacc.2021.02.048
- Fallick C, Sobotka PA, Dunlap ME. Sympathetically mediated changes in capacitance: redistribution of the venous reservoir as a cause of decompensation. *Circ Heart Fail.* 2011;4:669–675. doi: 10.1161/ circheartfailure.111.961789
- Gay R, Wool S, Paquin M, Goldman S. Total vascular pressure-volume relationship in conscious rats with chronic heart failure. *Am J Physiol.* 1986;251:H483–H489. doi: 10.1152/ajpheart.1986.251.3.H483
- Wang SY, Manyari DE, Scott-Douglas N, Smiseth OA, Smith ER, Tyberg JV. Splanchnic venous pressure-volume relation during experimental acute ischemic heart failure. Differential effects of hydralazine, enalaprilat, and nitroglycerin. *Circulation*. 1995;91:1205–1212. doi: 10.1161/01. cir.91.4.1205

- Grassi G, D'Arrigo G, Pisano A, Bolignano D, Mallamaci F, Dell'Oro R, Quarti-Trevano F, Seravalle G, Mancia G, Zoccali C. Sympathetic neural overdrive in congestive heart failure and its correlates: systematic reviews and meta-analysis. *J Hypertens*. 2019;37:1746–1756. doi: 10.1097/hjh.00000000002093
- Fudim M, Ganesh A, Green C, Jones WS, Blazing MA, DeVore AD, Felker GM, Kiefer TL, Kong DF, Boortz-Marx RL, et al. Splanchnic nerve block for decompensated chronic heart failure: splanchnic-HF. *Eur Heart J*. 2018;39:4255–4256. doi: 10.1093/eurheartj/ehy682
- Fudim M, Jones WS, Boortz-Marx RL, Ganesh A, Green CL, Hernandez AF, Patel MR. Splanchnic nerve block for acute heart failure. *Circulation*. 2018;138:951–953. doi: 10.1161/circulationaha.118.035260
- Fudim M, Boortz-Marx RL, Ganesh A, DeVore AD, Patel CB, Rogers JG, Coburn A, Johnson I, Paul A, Coyne BJ, et al. Splanchnic nerve block for chronic heart failure. *JACC Heart Fail*. 2020;8:742–752. doi: 10.1016/j.jchf.2020.04.010
- Fudim M, Patel MR, Boortz-Marx R, Borlaug BA, DeVore AD, Ganesh A, Green CL, Lopes RD, Mentz RJ, Patel CB, et al. Splanchnic nerve block mediated changes in stressed blood volume in heart failure. *JACC Heart Fail*. 2021;9:293–300. doi: 10.1016/j.jchf.2020.12.006
- Appelboam A, Reuben A, Mann C, Gagg J, Ewings P, Barton A, Lobban T, Dayer M, Vickery J, Benger J. Postural modification to the standard Valsalva manoeuvre for emergency treatment of supraventricular tachycardias (REVERT): a randomised controlled trial. *Lancet*. 2015;386:1747–1753. doi: 10.1016/s0140-6736(15)61485-4
- Smith ML, Beightol LA, Fritsch-Yelle JM, Ellenbogen KA, Porter TR, Eckberg DL. Valsalva's maneuver revisited: a quantitative method yielding insights into human autonomic control. *Am J Phys.* 1996;271:H1240–H1249. doi: 10.1152/ajpheart.1996.271.3.H1240
- Korner PI, Tonkin AM, Uther JB. Reflex and mechanical circulatory effects of graded Valsalva maneuvers in normal man. *J Appl Physiol*. 1976;40:434–440. doi: 10.1152/jappl.1976.40.3.434
- Nishimura RA, Tajik AJ. The Valsalva maneuver and response revisited. Mayo Clin Proc. 1986;61:211–217. doi: 10.1016/s0025-6196(12)61852-7
- McIntyre KM, Vita JA, Lambrew CT, Freeman J, Loscalzo J. A noninvasive method of predicting pulmonary-capillary wedge pressure. N Engl J Med. 1992;327:1715–1720. doi: 10.1056/nejm199212103272404
- Saxena M, Shour T, Shah M, Wolff CB, Julu POO, Kapil V, Collier DJ, Ng FL, Gupta A, Balawon A, et al. Attenuation of splanchnic autotransfusion following noninvasive ultrasound renal denervation: a novel marker of procedural success. J Am Heart Assoc. 2018;7:7. doi: 10.1161/ jaha.118.009151
- Kaptein MJ, Kaptein EM. Inferior vena cava collapsibility index: clinical validation and application for assessment of relative intravascular volume. Adv Chronic Kidney Dis. 2021;28:218–226. doi: 10.1053/j.ackd.2021.02.003
- Ivey-Miranda JB, Wetterling F, Gaul R, Sheridan S, Asher JL, Rao VS, Maulion C, Mahoney D, Mebazaa A, Gray AP, et al. Changes in inferior vena cava area represent a more sensitive metric than changes in filling pressures during experimental manipulation of intravascular volume and tone. *Eur J Heart Fail*. 2022;24:455–462. doi: 10.1002/ejhf.2395
- Ilyas A, Ishtiaq W, Assad S, Ghazanfar H, Mansoor S, Haris M, Qadeer A, Akhtar A. Correlation of IVC diameter and collapsibility index with central venous pressure in the assessment of intravascular volume in critically ill patients. *Cureus*. 2017;9:e1025. doi: 10.7759/cureus.1025
- Thibodeau JT, Turer AT, Gualano SK, Ayers CR, Velez-Martinez M, Mishkin JD, Patel PC, Mammen PP, Markham DW, Levine BD, et al. Characterization of a novel symptom of advanced heart failure: bendopnea. JACC Heart Fail. 2014;2:24–31. doi: 10.1016/j.jchf.2013.07.009
- Agostoni P, Wasserman K, Guazzi M, Cattadori G, Palermo P, Marenzi G, Guazzi MD. Exercise-induced hemoconcentration in heart failure due to dilated cardiomyopathy. *Am J Cardiol*. 1999;83:278–280. doi: 10.1016/s0002-9149(98)00839-x
- Harrison MH. Effects on thermal stress and exercise on blood volume in humans. *Physiol Rev.* 1985;65:149–209. doi: 10.1152/ physrev.1985.65.1.149
- Crosby WH. Normal functions of the spleen relative to red blood cells: a review. *Blood.* 1959;14:399–408. doi: 10.1182/blood.V14.4.399.399
- Stewart IB, McKenzie DC. The human spleen during physiological stress. Sports Med (Auckland, NZ). 2002;32:361–369. doi: 10.2165/0 0007256-200232060-00002
- Yaranov DM, Jefferies JL, Silver MA, Burkhoff D, Rao VN, Fudim M. Discordance of pressure and volume: potential implications for pressure-guided remote monitoring in heart failure. J Card Fail. 2022;28:870–872. doi: 10.1016/j.cardfail.2022.02.003

# **SUPPLEMENTAL MATERIAL**

Table S1. Changes in baseline hemodynamics and venous capacitance surrogates according to the intervention.

	Bilateral SNM (n=5)			Unilateral SNM (n=10)		
	Pre-SNM	Post-SNM	P-value	Pre-SNM	Post-SNM	P-value
Baseline Hemodynamics						
HR (BPM)	76 ± 13	86 ± 22	0.118	56 ± 12	56 ± 11	0.914
SBP (mmHg)	128 ± 24	108 ± 21	0.213	135 ± 17	129 ± 17	0.155
DBP (mmHg)	72 ± 9	58 ± 10	0.059	79 ± 13	73 ± 12	0.047
PP (mmHg)	56 ± 20	50 ± 15	0.524	56 ± 12	56 ± 11	0.914
RA (mmHg)	12.0 ± 5.9	6.2 ± 5.3	0.005	14.7 ± 2.7	9.9 ± 2.9	0.001
PCWP (mmHg)	22.6 ± 4.4	12.6 ± 5.7	0.001	31.1 ± 7.5	24.2 ± 8.7	0.001
IVC Changes						
IVC diameter (cm)	1.5 ± 0.5	1.1 ± 0.79	0.066	1.6 ± 0.6	1.4 ± 0.5	0.187
IVC collapsibility (decrease	3 (60%)	4 (80%)	0.37	2 (20%)	7 (70%)	0.015
>50% with inspiration)						
IVC diameter/RAP	$0.14 \pm 0.04$	0.21 ± 0.07	0.083	0.11 ± 0.04	0.15 ± 0.05	0.058
Self-reported Bendopnea	1 (20%)	0 (0%)	0.374	6 (60%)	2 (20%)	0.037
Hemoconcentration						
<ul> <li>Hb at rest (g/dL)</li> </ul>	13.5 ± 0.9	13.1 ± 0.9	0.16	12.6 ± 1.7	12.6 ± 1.6	1.00
• Hb at peak exercise (g/dL)	13.9 ± 1.1	13.5 ± 1.0	0.087	13.3 ± 2.0	13.1 ± 1.8	0.056
Hb changes after exercise	$0.5 \pm 0.4$	$0.4 \pm 0.5$	0.746*	0.7 ± 0.5	$0.5 \pm 0.4$	0.019*
(g/dL)						

Data are presented as mean ±SD. Asterisk (\*) indicates p-values calculated from repeated measures models. BP: blood pressure; Hb: hemoglobin; HR: heart rate; IVC: inferior vena cava; MAP: mean arterial pressure; PCWP: pulmonary capillary wedge pressure; PP: pulse pressure; RA: right atrial pressure; SBP: systolic blood pressure; SNM: splanchnic nerve modulation.





CPET: cardiopulmonary exercise stress test; SNM: splanchnic nerve modulation.



Figure S2. Individual changes in blood pressure during the Valsalva maneuver.

SBP: systolic blood pressure; SNM: splanchnic nerve modulation.





A) systolic blood pressure, B) diastolic blood pressure, C) pulse pressure. CI: confidence interval; LS: least square; SNM: splanchnic nerve modulation.

Figure S4. Least-Square means plots for changes in hemoglobin levels during exercise.



CI: confidence interval; LS: least square; SNM: splanchnic nerve modulation.